- Medicine Name: Retevmo
- Generic Name: Selpercatinib
- Dosage Form & Strength: Capsules: 40/80 mg
- Manufactured By: Eli Lilly and Company
- Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.
- Adult and pediatric patients aged 12 years and older with advanced or metastatic RET fusion +Ve thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.